Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
Search
Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks
Mastitis dairy cows prevent antibiotic resistance
The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
Aservo EquiHaler wins Pharmapack Award 2021
Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
EFPIA disclosure
Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations.
Bringing focus to biliary tract and pancreatic cancers
The Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced biliary tract and pancreatic cancers.
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
New vaccine against Bovine Respiratory Disease
Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
Winners of BVDzero Scholarship Programme
Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
Digital innovation: Our digital pipeline is only growing
BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.
Mental health: a $1 trillion burden demanding policy action
Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Shared science for the best cat diabetes management
Diabetes mellitus is a common endocrine disease with increasing prevalence in dogs and cats. Learn how science's made management easier.
Making-more-health-together-2021
1,200 participants from around the world join virtual convention on November 11-12
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
collaboration criving innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Facts about the INPULSIS™ trials
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes